Publications by authors named "Benjamin Bleicken"
Health related quality of life (HRQoL) is impaired in adult patients with 21-hydroxylase deficiency (21-OHD). Up to now, only cross-sectional and no longitudinal studies are available. It is not known if HRQoL can be improved in adult 21-OHD patients.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates health-related quality of life (HRQoL) in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency and compares it with primary adrenal insufficiency (PAI) and healthy controls.
- CAH patients reported mild impairments in HRQoL, specifically in three aspects, but did not show significant differences in other assessments compared to healthy controls; however, PAI patients had worse HRQoL across more areas.
- The findings imply that HRQoL in CAH is better than in PAI patients, suggesting that factors other than hormone replacement therapy may influence the quality of life in these patients.
Introduction: Little information is available on patients with adrenal insufficiency (AI) in regard to complaints before diagnosis, time until correct diagnosis, false diagnosis, and professional changes due to the diagnosis.
Objective: We retrospectively evaluated circumstances before and at diagnosis of AI in patients with primary and secondary AI by using established Hospital Anxiety and Depression Scale, Short Form-36 and Giessen Complaint List (GBB-24) questionnaires, and a self-established general registration form.
Methods: In this cross-sectional study, questionnaire sets were available from 216 patients (primary AI, n = 99; secondary AI, n = 117).
Objective: Adrenal crisis (AC) is a life-threatening complication of adrenal insufficiency (AI). Here, we evaluated frequency, causes and risk factors of AC in patients with chronic AI.
Methods: In a cross-sectional study, 883 patients with AI were contacted by mail.
Article Synopsis
- Recent studies indicate that glucocorticoid replacement therapies, like hydrocortisone (HC), do not fully restore health-related quality of life (QoL) for patients with adrenal insufficiency (AI).
- In a study with 334 AI patients, those on higher HC doses (>30 mg/day) reported worse health status, while no significant QoL differences were noted between lower doses or types of AI.
- The findings suggest that taking HC three times daily did not improve QoL compared to twice daily, highlighting that current treatment strategies still leave patients feeling unwell and underperforming.
Context: Recent studies have suggested that current glucocorticoid replacement therapies fail to fully restore well-being in patients with adrenal insufficiency (AI).
Objective: To investigate the effect of different glucocorticoid preparations used for replacement therapy on subjective health status (SHS) in AI.
Design And Patients: In a cross-sectional study, primary and secondary AI patients were contacted by mail.